Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación y derecho · 10/9/20251 min de lectura
Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers
Traducción automática local · Idioma original de la fuente
Resumen
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.
Idioma original de la fuente: Federal Register — All DocumentsAbrir el comunicado original →